PURPOSE: Tumors expressing high levels of CYP3A4 are likely to have a poor treatment response to docetaxel (DOC), which is metabolized by CYP3A4. Tissue samples of recurrent breast cancer are sometimes hard to obtain just before treatment because the tumor is often difficult to access. Using immunohistochemistry, we measured CYP3A4 expression in primary lesions and compared their treatment responses to DOC with those of recurrent breast cancer lesions. METHODS: The subjects of this study were 42 patients who had undergone surgery for breast cancer, and had metastasis or recurrence treated by DOC (60 mg/m(2) every 3 weeks). Tumor samples resected at surgery were immunostained for CYP3A4 and its expression levels were compared with the response rate to ongoing DOC treatment. RESULTS: Patients with CYP3A4-negative tumors (n = 19) showed a significantly higher response rate (63.2%) to DOC treatment than did those with CYP3A4-positive tumors (n = 23) (26.1%). The predictive value, negative predictive value, and diagnostic accuracy of CYP3A4 expression in the prediction response to DOC were 63.2%, 73.9%, and 68.6%, respectively. CONCLUSIONS: Measuring CYP3A4 expression immunohistochemically in the primary breast cancer lesion was useful for predicting the treatment response to DOC of tumors that recurred after a long interval.
PURPOSE:Tumors expressing high levels of CYP3A4 are likely to have a poor treatment response to docetaxel (DOC), which is metabolized by CYP3A4. Tissue samples of recurrent breast cancer are sometimes hard to obtain just before treatment because the tumor is often difficult to access. Using immunohistochemistry, we measured CYP3A4 expression in primary lesions and compared their treatment responses to DOC with those of recurrent breast cancer lesions. METHODS: The subjects of this study were 42 patients who had undergone surgery for breast cancer, and had metastasis or recurrence treated by DOC (60 mg/m(2) every 3 weeks). Tumor samples resected at surgery were immunostained for CYP3A4 and its expression levels were compared with the response rate to ongoing DOC treatment. RESULTS:Patients with CYP3A4-negative tumors (n = 19) showed a significantly higher response rate (63.2%) to DOC treatment than did those with CYP3A4-positive tumors (n = 23) (26.1%). The predictive value, negative predictive value, and diagnostic accuracy of CYP3A4 expression in the prediction response to DOC were 63.2%, 73.9%, and 68.6%, respectively. CONCLUSIONS: Measuring CYP3A4 expression immunohistochemically in the primary breast cancer lesion was useful for predicting the treatment response to DOC of tumors that recurred after a long interval.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: C Simon; B Stieger; G A Kullak-Ublick; M Fried; S Mueller; J-M Fritschy; H G Wieser; C Pauli-Magnus Journal: Acta Neurol Scand Date: 2007-04 Impact factor: 3.209
Authors: M Crump; C A Sawka; G DeBoer; R B Buchanan; J N Ingle; J Forbes; J W Meakin; W Shelley; K I Pritchard Journal: Breast Cancer Res Treat Date: 1997-07 Impact factor: 4.872
Authors: E Kirches; C Scherlach; P von Bossanyi; T Schneider; R Szibor; E Kutz; M Warich-Kirches; K Dietzmann Journal: Clin Neuropathol Date: 1999 Jan-Feb Impact factor: 1.368
Authors: W W ten Bokkel Huinink; A M Prove; M Piccart; W Steward; T Tursz; J Wanders; H Franklin; M Clavel; J Verweij; M Alakl Journal: Ann Oncol Date: 1994-07 Impact factor: 32.976
Authors: Maarten van Eijk; René J Boosman; Alfred H Schinkel; Alwin D R Huitema; Jos H Beijnen Journal: Cancer Chemother Pharmacol Date: 2019-07-15 Impact factor: 3.333